Target intelligence / Profile preview

Pvs230 protein (Plasmodium vivax) (Pvs230)

Target: Pvs230
Molecular classification: Gametocyte/gamete surface antigen, 6-cysteine protein family, Transmission-blocking vaccine target

Overview

Pvs230 is a large, multidomain surface protein expressed by Plasmodium vivax on gametocytes and gametes, belonging to the 6-cysteine (6-Cys) protein family, characterized by multiple conserved cysteine-rich domains[1][4]. Its N-terminal domain (domain 1, or Pvs230D1) contains immunogenic epitopes that elicit transmission-blocking antibodies and is under study as a major candidate antigen for malaria transmission-blocking vaccines[2][4]. The biological function mirrors its Plasmodium falciparum ortholog (Pfs230), being essential for male gamete fertility, gamete recognition, and possibly parasite binding to human erythrocytes. Antibodies against Pvs230, particularly against the D1 domain, can block parasite transmission to mosquitoes, making it a leading candidate for next-generation malaria vaccines aimed at interrupting transmission[2][4].

Other names: Pvs230D1 proteinPvs230 domain 1Pvs230D1M

Mechanism of action

Transmission blocking via antibody-mediated inhibition of parasite fertilization in the mosquito

Biological functions

Surface localization on sexual-stage parasites (gametocytes and gametes)Involved in parasite fertilization and transmission to mosquitoesPotential role in gamete recognition and host cell (erythrocyte) interaction

Disease associations

Infection (malaria; specifically Plasmodium vivax transmission)

Safety considerations

No major safety concerns documented for targeting Pvs230; potential challenge is antigenic diversity and the need to induce functional, complement-fixing antibodies

Interacting drugs

None currently approved; monoclonal antibodies (experimental) targeting this protein

Biomarkers

None established for clinical use; anti-Pvs230 antibody levels explored as surrogate of transmission-blocking immunity

Beyond the preview

Go deeper on Pvs230 protein (Plasmodium vivax) (Pvs230).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

Drug candidates
Developers
Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

Trial design
Status
Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

Programs
Modalities
Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

Publications
Sources
Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

Patents
Assignees
Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

Biology
Development news
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Pvs230 protein (Plasmodium vivax) (Pvs230).

Explore the full profile